Loading clinical trials...
Loading clinical trials...
Response Rate and Response Duration After Discontinuation of Treatment With Thrombopoietin Receptor Agonists in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study
The primary objective of the study is the evaluation of sustained response rate after discontinuation of treatment with TPO-RAs, Eltrombopag and Romiplostim, in persistent or chronic pITP patients who failed one or more therapy lines, splenectomy included.
Increasing evidence exists in the literature on the persistent response after TPO-RAs discontinuation. However, the available data consist of description of case reports from different patients' series. At this time, systematic data collections on this topic do not exist and the real incidence of such persistent response is unknown. Therefore, because of the increasing interest in this new and challenging therapeutic field, also for the therapeutic implications, we would like to investigate the impact of TPO- RAs on the achievement of sustained and persistent responses after their discontinuation in the Italian adult patients affected by pITP who have been referred to the GIMEMA Centers.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
S.O.C. di Medicina Interna B - Ospedale - Cardinal Massaia di Asti
Asti, Italy
Istituto di Ematologia "Lorenzo e A. Seragnoli"
Bologna, Italy
Unità di Onco-Ematologia - Azienda Ospedaliera - Garibaldi
Catania, Italy
Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano
Florence, Italy
Clinica Medica III - Padiglione ex isolamento - Azienda Ospedale Università San Martino
Genova, Italy
ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE
Lecce, Italy
Azienda Ospedaliera "S.Gerardo"
Monza, Italy
Ematologia - Ospedale San Carlo
Potenza, Italy
Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova
Reggio Emilia, Italy
Università Cattolica del Sacro Cuore - Policlinico A. Gemelli
Roma, Italy
Start Date
April 1, 2016
Primary Completion Date
April 17, 2019
Completion Date
April 17, 2019
Last Updated
April 29, 2025
148
ACTUAL participants
Eltrombopag
DRUG
Romiplostin
DRUG
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT07104565
NCT07362199
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07362238